Neurodegeneration in the brain tumor microenvironment: Glutamate in the limelight

Current Neuropharmacology

Volumn 13, Issue 2, 2015, Pages 258-265

  Savaskan, Nicolai E ^a   Fan, Zheng ^a   Broggini, Thomas ^b   Buchfelder, Michael ^a   Eyüpoglu, Ilker Y ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

GBM; Glutamate; Neuron; NMDA; ROS; SystemX; TRP; XCT

Indexed keywords

CLUSTERIN; CYSTINE; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2; AMINO ACID TRANSPORTER; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ASTROCYTE; BRAIN TUMOR; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); GLIOMA; HUMAN; MICROGLIA; NERVE DEGENERATION; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN NEOPLASMS; COMPLICATION; DRUG EFFECTS; METABOLISM; MOLECULAR MODEL; PATHOLOGY;

AMINO ACID TRANSPORT SYSTEMS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN NEOPLASMS; GLUTAMIC ACID; HUMANS; MODELS, MOLECULAR; NERVE DEGENERATION; REACTIVE OXYGEN SPECIES; SULFASALAZINE; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84930718684     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666150122224158     Document Type: Article

References (82)

1. [1] Dolecek, T.A., Propp, J.M., Stroup, N.E., Kruchko, C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol., 2012, 14 Suppl 5, v1-49. http://dx.doi.org/10.1093/neuonc/nos218
2. [2] Furnari, F.B., Fenton, T., Bachoo, R.M., Mukasa, A., Stommel, J.M., Stegh, A., Hahn, W.C., Ligon, K.L., Louis, D. N., Brennan, C., Chin, L., DePinho, R.A., Cavenee, W.K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev., 2007, 21, 2683-710. http://dx.doi.org/10.1101/gad.1596707
3. [3] Eyupoglu, I.Y., Buchfelder, M., Savaskan, N.E. Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat. Rev. Neurol., 2013, 9, 141-51. http://dx.doi.org/10.1038/nrneurol.2012.279
4. [4] Wen, P.Y., Kesari, S. Malignant gliomas in adults. N. Engl. J. Med., 2008, 359, 492-507. http://dx.doi.org/10.1056/NEJMra0708126
5. [5] Savaskan, N.E., Heckel, A., Hahnen, E., Engelhorn, T., Doerfler, A., Ganslandt, O, Nimsky, C., Buchfelder, M., Eyupoglu, Y. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med., 2008, 14, 629-32. http://dx.doi.org/10.1038/nm1772
6. [6] Savaskan, N.E., Eyupoglu, I.Y. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Ann. Anat., 2010, 192, 309-13. http://dx.doi.org/10.1016/j.aanat.2010.07.003
7. [7] Hanahan, D., Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144, 646-74. http://dx.doi.org/10.1016/j.cell.2011.02.013
8. [8] Flavahan, W.A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A.E., Weil, R.J., Nakano, I., Sarkaria, J.N., Stringer, B.W., Day, B.W., Li, M., Lathia, D. J., Rich, J.N., Hjelmeland, A.B. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci., 2013,16, 1373-82. http://dx.doi.org/10.1038/nn.3510
9. [9] Geier, E.G., Chen, E.C., Webb, A., Papp, A.C., Yee, S.W., Sadee, W, Giacomini, K.M. Profiling solute carrier transporters in the human blood-brain barrier. Clin. Pharmacol. Ther., 2013, 94, 636-9. http://dx.doi.org/10.1038/clpt.2013.175
10. [10] Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124, 269-70.
11. [11] Ganapathy, V., Thangaraju, M., Prasad, P.D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther., 2009, 121, 29-40. http://dx.doi.org/10.1016/j.pharmthera.2008.09.005
12. [12] Dang, C.V. Links between metabolism and cancer. Genes Dev., 2012, 26, 877-90. http://dx.doi.org/10.1101/gad.189365.112
13. [13] Martinez-Outschoorn, U., Sotgia, F., Lisanti, M.P. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin. Oncol., 2014, 41, 195-216. http://dx.doi.org/10.1053/j.seminoncol.2014.03.002
14. [14] Kroemer, G., Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13, 472-82. http://dx.doi.org/10.1016/j.ccr.2008.05.005
15. [15] Semenza, G.L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med., 2003, 54, 17-28. http://dx.doi.org/10.1146/annurev.med.54.101601.152418
16. [16] Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba, Y. Acidic extracellular microenvironment and cancer. Cancer Cell Int., 2013, 13,89. http://dx.doi.org/10.1186/1475-2867-13-89
17. [17] Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J.A., Corce, C.M., Plunkett, W., Keating, M.J., Haung, P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol., 2012, 14, 276-86. http://dx.doi.org/10.1038/ncb2432
18. [18] Garnier, N., Redstone, G.G., Dahabieh, M.S., Nichol, J.N., del Rincon, S.V., Gu, Y., Bohle, D.S., Sun, Y., Conklin, D.S., Mann, K.K., Miller, W.H. Jr. The novel arsenical darinaparsin is transported by cystine importing systems. Mol. Pharmacol., 2014, 85, 576-85. http://dx.doi.org/10.1124/mol.113.089433
19. [19] Banjac, A., Perisic, T., Sato, H., Seiler, A., Bannai, S., Weiss, N., Kolle, P., Tschoep, K., Issels, R.D., Daniel, P.T., Conrad, M., Bornkamm, G.W. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene, 2008, 27, 1618-28. http://dx.doi.org/10.1038/sj.onc.1210796
20. [20] Chen, R.S., Song, Y.M., Zhou, Z.Y., Tong, T., Li, Y., Fu, M., Guo, X.L., Dong, L.J., He, X., Qiao, H.X., Zhan, Q.M., Li M. Disruption of xCT inhibits cancer cell metastasis via the caveolin- 1/beta-catenin pathway. Oncogene, 2009, 28, 599-609. http://dx.doi.org/10.1038/onc.2008.414
21. [21] Dai, L., Cao, Y., Chen, Y., Parsons, C., Qin, Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J. Hematol. Oncol., 2014, 7, 30. http://dx.doi.org/10.1186/1756-8722-7-30
22. [22] Qin, Z., Freitas, E., Sullivan, R., Mohan, S., Bacelieri, R. Branch D, Romano, M., Kearny, P., Oates, J., Plaisance, K., Renne, R., Kaleeba, J., Parsons, C. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog., 2010, 6, e1000742. http://dx.doi.org/10.1371/journal.ppat.1000742
23. [23] Huang, Y., Dai, Z., Barbacioru, C., Sadee, W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res., 2005, 65, 7446-54. http://dx.doi.org/10.1158/0008-5472.CAN-04-4267
24. [24] Timmerman, L.A., Holton, T., Yuneva, M., Louie, R.J., Padro, M., Daemen, A, Hu, M., Chan, D.M., Ethier, S.P., van’ T, Veer, L.J., Polyak, K., McCormic, F., Gray, J.W. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell, 2013, 24, 450-65. http://dx.doi.org/10.1016/j.ccr.2013.08.020
25. [25] Wang, F., Yang, Y. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat., 2014, 147, 203-10. http://dx.doi.org/10.1007/s10549-014-3068-6
26. [26] Yoshikawa, M., Tsuchihashi, K., Ishimoto, T., Yae, T., Motohara, T., Sugihara, E., Onishi, N., Masuko, T., Yoshizhawa, K., Kawashiri, K., Mukai, M., Asoda, S., Kawan, H., Nakagawa, T., Saya, H., Nagano, O. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res., 2013, 73, 1855-66. http://dx.doi.org/10.1158/0008-5472.CAN-12-3609-T
27. [27] Toyoda, M., Kaira, K., Ohshima, Y., Ishioka, N.S., Shino, M., Sakakura, K, Takayasu, Y., Takahasi, K., Tominaga, H., Oruchi, N., Nagamori, S., Kanayi, Y., Oyama, T., Chikamatsu, K. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br. J Cancer, 2014, 110, 2506-13. http://dx.doi.org/10.1038/bjc.2014.178
28. [28] Kim, J.Y., Kanai, Y., Chairoungdua, A, Cha, S.H., Matsuo, H., Kim, D.K., Inatomi, J., Sawa, H., Iday, Y., Endou, H. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim. Biophys. Acta, 2001, 1512, 335-44. http://dx.doi.org/10.1016/S0005-2736(01)00338-8
29. [29] Chairoungdua, A., Kanai, Y., Matsuo, H., Inatomi, J., Kim, D.K., Endou, H. Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain. J. Biol. Chem., 2001, 276, 49390-9. http://dx.doi.org/10.1074/jbc.M107517200
30. [30] Bannai, S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem., 1986, 261, 2256-63.
31. [31] Patel, S.A., Warren, B.A., Rhoderick, J.F., Bridges, R.J. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology, 2004, 46, 273-84. http://dx.doi.org/10.1016/j.neuropharm.2003.08.006
32. [32] Reddy, N.M., Kleeberger, S.R., Bream, J.H., Fallon, P.G., Kensler, T.W., Yamamoto, M., Reddy, S.P. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene, 2008,27, 5821-32.
33. [33] Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E.K., Culmsee C, Plesnila, N., Kremmer, E., Radmark, O., Wurst, W., Bornkamm, G.W., Schweizer, U., Conrad, M. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15- lipoxygenase dependent- and AIF-mediated cell death. Cell Metab., 2008, 8, 237-48. http://dx.doi.org/10.1016/j.cmet.2008.07.005
34. [34] Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H, Sohda, S, Hamada, H., Yoshikhawa, H., Kondo, T., Bannai, S. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer, 2003, 88, 951-6. http://dx.doi.org/10.1038/sj.bjc.6600786
35. [35] Robert, S.M., Ogunrinu-Babarinde, T., Holt, K.T., Sontheimer, H. Role of glutamate transporters in redox homeostasis of the brain. Neurochem. Int., 2014, 73, 181-91. http://dx.doi.org/10.1016/j.neuint.2014.01.001
36. [36] Savaskan, N.E., Seufert, S., Hauke, J., Trankle, C., Eyupoglu, I.Y., Hahnen, E. Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas. Oncogene, 2011, 30, 43-53. http://dx.doi.org/10.1038/onc.2010.391
37. [37] Uchihori, Y., Puro, D.G. Glutamate as a neuron-to-glial signal for mitogenesis: role of glial N-methyl-D-aspartate receptors. Brain Res., 1993, 613,212-20. http://dx.doi.org/10.1016/0006-8993(93)90901-X
38. [38] Nedergaard M, Takano T, Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci., 2002, 3, 748-55. http://dx.doi.org/10.1038/nrn916
39. [39] Martel, M.A., Ryan, T.J., Bell, K.F., Fowler, J.H., McMahon, A., Al-Mubarak, B., Komiyama, N.H., Horshburgh, K., Kind, P.C., Grant, S.G., Wyllie, D.J., Hardingham, G.E. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron, 2012, 74, 543-56. http://dx.doi.org/10.1016/j.neuron.2012.03.021
40. [40] Beal, M.F. Mechanisms of excitotoxicity in neurologic diseases. FASEB J., 1992, 6, 3338-44.
41. [41] Gupta, K., Hardingham, G.E., Chandran, S. NMDA receptordependent glutamate excitotoxicity in human embryonic stem cellderived neurons. Neurosci. Lett., 2013, 543, 95-100. http://dx.doi.org/10.1016/j.neulet.2013.03.010
42. [42] Takano, T., Lin, J.H., Arcuino, G., Gao, Q., Yang, J., Nedergaard, M. Glutamate release promotes growth of malignant gliomas. Nat. Med., 2001, 7, 1010-5. http://dx.doi.org/10.1038/nm0901-1010
43. [43] Buckingham, S.C., Campbell, S.L., Haas, B.R., Montana, V., Robel, S., Ogunrinu, T., Sontheimer, H. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med., 2011, 17, 1269-74. http://dx.doi.org/10.1038/nm.2453
44. [44] Behrens, P.F., Langemann, H., Strohschein, R., Draeger, J., Hennig, J. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J. Neurooncol., 2000, 47, 11-22. http://dx.doi.org/10.1023/A:1006426917654
45. [45] Marcus, H.J., Carpenter, K.L., Price, S.J., Hutchinson, P.J. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J. Neurooncol., 2010, 97, 11-23. http://dx.doi.org/10.1007/s11060-009-9990-5
46. [46] Ye, Z.C., Sontheimer, H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res., 1999, 59, 4383-91.
47. [47] Vanhoutte, N., Abarca-Quinones, J., Jordan, B.F., Gallez, B., Maloteaux, J.M., Hermans, E. Enhanced expression of the high affinity glutamate transporter GLT-1 in C6 glioma cells delays tumour progression in rat. Exp. Neurol., 2009, 218,56-63. http://dx.doi.org/10.1016/j.expneurol.2009.04.004
48. [48] Lyons, S.A., Chung, W.J., Weaver, A.K., Ogunrinu, T., Sontheimer, H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res., 2007, 67, 9463-71. http://dx.doi.org/10.1158/0008-5472.CAN-07-2034
49. [49] Chung, W.J., Lyons, S.A., Nelson, G.M., Hamza, H., Gladson, C.L., Gillespie, G.Y., Gillespie, G.Y., Sontheimer, H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci., 2005, 25, 7101-10. http://dx.doi.org/10.1523/JNEUROSCI.5258-04.2005
50. [50] Yoshida, Y., Tsuzuki, K, Ishiuchi, S., Ozawa, S. Serumdependence of AMPA receptor-mediated proliferation in glioma cells. Pathol. Int., 2006, 56, 262-71. http://dx.doi.org/10.1111/j.1440-1827.2006.01954.x
51. [51] Ishiuchi, S., Yoshida, Y., Sugawara, K., Aihara, M., Ohtani, T., Watanabe, T., Ohtani, T., Saito, N., Tsuzuki, K., Okado, H., Miwa, A., Nakazato, Y., Oszawa, S. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J. Neurosci. 2007, 27, 7987-8001. http://dx.doi.org/10.1523/JNEUROSCI.2180-07.2007
52. [52] Ishiuchi, S., Tsuzuki, K., Yoshida, Y., Yamada, N., Hagimura, N., Okado, H., Miwa, A., Kurihara, H., Nakazato Y., Tamura, M., Sasaki, T., Ozawa, S. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med., 2002, 8, 971-8. http://dx.doi.org/10.1038/nm746
53. [53] Nabissi, M., Morelli, M.B., Amantini, C., Farfariello, V., Ricci- Vitiani, L., Caprodossi, S, Arcella, A., Santoni, M., Giangaspero, F., De Maria, R., Santoni, G. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis, 2010, 31, 794-803. http://dx.doi.org/10.1093/carcin/bgq019
54. [54] Yue, H.Y., Jiang, C.Y., Fujita, T, Kumamoto, E. Zingerone enhances glutamatergic spontaneous excitatory transmission by activating TRPA1 but not TRPV1 channels in the adult rat substantia gelatinosa. J. Neurophysiol., 2013, 110, 658-71. http://dx.doi.org/10.1152/jn.00754.2012
55. [55] Nishio, N., Taniguchi, W., Sugimura, Y.K., Takiguchi, N., Yamanaka M, Kiyoyuki, Y., Yamada, H., Miyazaki, N., Yoshida, M., Nakatsuka, T. Reactive oxygen species enhance excitatory synaptic transmission in rat spinal dorsal horn neurons by activating TRPA1 and TRPV1 channels. Neuroscience, 2013, 247, 201-12. http://dx.doi.org/10.1016/j.neuroscience.2013.05.023
56. [56] Shimizu, S., Takahashi, N., Mori, Y. TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters). Handbook of experimental Pharmacology, 2014, 223, 767-94. http://dx.doi.org/10.1007/978-3-319-05161-1_3
57. [57] Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, Giangaspero, F., Santoni, G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem., 2007, 102,977-90. http://dx.doi.org/10.1111/j.1471-4159.2007.04582.x
58. [58] Ding, X., He, Z, Zhou, K., Cheng, J., Yao, H., Lu, D., Cai, R., Jin, Y., Dong, B., Xu, Y., Wang, Y. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J. Natl. Cancer Inst., 2010, 102, 1052-68. http://dx.doi.org/10.1093/jnci/djq217
59. [59] Stock, K., Kumar, J., Synowitz, M., Petrosino, S., Imperatore, R., Smith, E.S., Wend, P., Purfurst, B., Nuber, U.A., Gurok, U., Matyash, V., Walzlein, J.H., Chirasani, S.R., Dittmar, G., Cravatt, B.F., Momma, S., Lewin, G.R., Ligresti, A., De Petrocellis, L., Cristino, L., Di Marzo, V., Kettenmann, H., Glass, R. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat. Med., 2012, 18, 1232-8. http://dx.doi.org/10.1038/nm.2827
60. [60] Nabissi, M., Morelli, M.B., Santoni, M., Santoni, G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis, 2013, 34, 48-57. http://dx.doi.org/10.1093/carcin/bgs328
61. [61] Gottlieb, M., Matute, C. Expression of ionotropic glutamate receptor subunits in glial cells of the hippocampal CA1 area following transient forebrain ischemia. J. Cereb. Blood Flow Metab., 1997, 17, 290-300. http://dx.doi.org/10.1097/00004647-199703000-00006
62. [62] Dzamba, D., Honsa, P., Anderova, M. NMDA Receptors in Glial Cells: Pending Questions. Curr. Neuropharmacol., 2013, 11, 250-62. http://dx.doi.org/10.2174/1570159X11311030002
63. [63] Butt, A.M., Fern, R.F., Matute, C. Neurotransmitter signaling in white matter. Glia, 2014, 62,1762-79. http://dx.doi.org/10.1002/glia.22674
64. [64] Soria, F.N., Perez-Samartin, A., Martin, A., Gona, K.B., Llop, J., Szczupak, B., Chara, J.C., Matute, C., Domercq, M. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J. Clin. Invest., 2014, 124, 3645-55. http://dx.doi.org/10.1172/JCI71886
65. [65] Rosenberg, P.A. Accumulation of extracellular glutamate and neuronal death in astrocyte-poor cortical cultures exposed to glutamine. Glia, 1991, 4, 91-100. http://dx.doi.org/10.1002/glia.440040111
66. [66] Domercq, M., Vazquez-Villoldo, N., Matute, C. Neurotransmitter signaling in the pathophysiology of microglia. Front. Cell Neurosci., 2013, 7, 49. http://dx.doi.org/10.3389/fncel.2013.00049
67. [67] Kigerl, K.A., Ankeny, D.P., Garg, S.K., Wei, P., Guan, Z., Lai, W., McTigue, DM., Banerjee, R., Popovich, P.G. System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp. Neurol., 2012, 233, 333-41. http://dx.doi.org/10.1016/j.expneurol.2011.10.025
68. [68] Klegeris, A., Walker, D.G., McGeer, P.L. Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. J. Neuroimmunol., 1997, 78, 152-61. http://dx.doi.org/10.1016/S0165-5728(97)00094-5
69. [69] Eaton, S.A., Jane, D.E., Jones, P.L., Porter, R.H., Pook, P.C., Sunter, D.C., Udvarhelyi, P.M., Roberts, P.J., Salt, T.E., Watkins, J.C. Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4- carboxyphenylglycine. Eur. J. Pharmacol., 1993, 244, 195-7. http://dx.doi.org/10.1016/0922-4106(93)90028-8.
70. [70] Hayashi, Y., Sekiyama, N., Nakanishi, S., Jane, D.E., Sunter, D.C., Birse E.F., Udvarhelyi, P.M., Watkins, J.C. Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor subtypes. J. Neurosci., 1994, 14, 3370-7.
71. [71] Bedingfield, J.S., Kemp, M.C., Jane, D.E., Tse, H.W., Roberts, P.J., Watkins, J.C. Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs). Br. J. Pharmacol., 1995, 116, 3323-9. http://dx.doi.org/10.1111/j.1476-5381.1995.tb15142.x
72. [72] Sato, H., Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S. Redox imbalance in cystine/glutamate transporterdeficient mice. J. Biol. Chem., 2005, 280, 37423-9. http://dx.doi.org/10.1074/jbc.M506439200
73. [73] Liu, R.R., Brown, C.E., Murphy, T.H. Differential regulation of cell proliferation in neurogenic zones in mice lacking cystine transport by xCT. Biochem. Biophys. Res. Commun., 2007, 364, 528-33. http://dx.doi.org/10.1016/j.bbrc.2007.10.036
74. [74] Iuchi, Y., Kibe, N., Tsunoda, S., Okada, F., Bannai, S., Sato, H., Fujii, J. Deficiency of the cystine-transporter gene, xCT, does not exacerbate the deleterious phenotypic consequences of SOD1 knockout in mice. Mol. Cell Biochem., 2008, 319, 125-32. http://dx.doi.org/10.1007/s11010-008-9885-3
75. [75] McCullagh EA, Featherstone DE. Behavioral characterization of system xc- mutant mice. Behav. Brain Res., 2014, 265, 1-11. http://dx.doi.org/10.1016/j.bbr.2014.02.010
76. [76] Gout, P.W., Buckley, A.R., Simms, C.R., Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia, 2001, 15, 1633-40. http://dx.doi.org/10.1038/sj.leu.2402238
77. [77] Robe, P.A., Bentires-Alj, M., Bonif, M., Rogister, B., Deprez, M., Haddada, H., Khac, M.T., Jolois, O., Erkmen, K., Merville, M.P., Black, P.M., Bours, V. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin. Cancer Res., 2004, 10, 5595-603. http://dx.doi.org/10.1158/1078-0432.CCR-03-0392
78. [78] Pentikainen, V., Suomalainen, L., Erkkila, K., Martelin, E., Parvinen M., Pentikainen, M.O., Dunkel, L. Nuclear factor-kappa B activation in human testicular apoptosis. Am. J. Pathol., 2002, 160, 205-18. http://dx.doi.org/10.1016/S0002-9440(10)64364-7
79. [79] Hayeshi, R., Mutingwende I, Mavengerem, W., Masiyanise, V., Mukanganyama, S. The inhibition of human glutathione Stransferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol., 2007, 45, 286-95. http://dx.doi.org/10.1016/j.fct.2006.07.027
80. [80] Hasko, G., Szabo, C., Nemeth, Z.H., Deitch, E.A. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology, 2001, 103, 473-8. http://dx.doi.org/10.1046/j.1365-2567.2001.01272.x
81. [81] Dixon, S.J., Patel, D.N., Welsch, M., Skouta, R., Lee, E.D., Hayano, M., Thomas, A.G., Gleason, C.E., Tatonetti, N.P., Slusher, B.S., Stockwell, B.R.. Pharmacological inhibition of cystineglutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 2014, 3, 02523. http://dx.doi.org/10.7554/eLife.02523
82. [82] Wolf, I.M., Fan, Z., Rauh, M., Seufert, S., Hore, N., Buchfelder, M., Savaskan, N.E., Eyupoglu, I.Y. Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration. Sci. Reports, 2014, 4, 6226. http://dx.doi.org/10.1038/srep06226